Christian Mandl | CSO
Tiba Biotech

Christian W. Mandl is a consultant for industrial, academic and non-profit organizations on translational aspects of vaccines, cancer immunotherapy and global health. His engagement with the health care industry and public health organizations includes roles as Co-founder and Chief Scientific Officer for Tiba Biotech (Boston, USA), Senior Advisor at Adjuvant Capital (New York, USA), and Trustee at the International Vaccine Institute (Seoul, Korea). Previously he was the Senior Vice President of RNA Research for VIR Bio (San Francisco, USA), and the Chair of the Scientific Advisory Board for Themis Bioscience (Vienna, Austria). Until 2015, he was Global Head of Research, Early and Exploratory Clinical Development at Novartis Vaccines, where he led a global team of more than 300 discovery and clinical researchers developing a broad range of viral and bacterial vaccines, adjuvants and delivery platforms including the self-amplifying mRNA technology, which he initiated inspired by his previous academic research. Prior to joining Novartis in 2008, Christian was Professor of Virology and Assistant Head of the Clinical Institute of Virology at Medical University of Vienna, Austria. He has authored more than 100 scientific publications and is an inventor on patents for vaccine and RNA technologies. He holds a MSc in Biochemistry (1985) from Penn State University, a PhD in Biochemistry (1988) and a MD (1993) from University of Vienna, as well as a Certification as a Medical Specialist in Virology (1999) from the Austrian Medical Association. Linkedin.com/in/cwmandl